MCM
PTCT icon

Matarin Capital Management’s PTC Therapeutics PTCT Stock Holding History

Matarin Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-14,068
Closed -$475K – 306
2018
Q2 		$475K Hold
14,068
– – 0.03% 252
2018
Q1 		$381K Sell
14,068
-2,519
-15% -$63.8K 0.03% 259
2017
Q4 		$277K Sell
16,587
-170,486
-91% -$2.89M 0.02% 275
2017
Q3 		$3.74M Buy
187,073
+36,472
+24% +$714K 0.32% 127
2017
Q2 		$2.76M Buy
150,601
+132,288
+722% +$1.78M 0.26% 146
2017
Q1 		$180K Buy
+18,313
New +$222K 0.02% 272

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Matarin Capital Management's PTCT Position: Q3 2018 in Review

Matarin Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 14,068 shares — an estimated $475K sold.

Matarin Capital Management first reported a position in PTCT in Q1 2017 and held it in 6 quarters. The position peaked at $3.74M in Q3 2017. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

  • Matarin Capital Management reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Matarin Capital Management sold 14,068 PTC Therapeutics shares in Q3 2018, an estimated $475K.
  • Matarin Capital Management first reported a position in PTC Therapeutics in Q1 2017 and held it in 6 quarters.
  • Matarin Capital Management's PTC Therapeutics position peaked at $3.74M in Q3 2017.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on Matarin Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.